Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sorich

Showing results (61-70 of 216) with videos related to

Pageof 22
Sort By:
BMC Cancer|February 28, 2020
Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trialsAshley M Hopkins, Akash D Rathod, Andrew Rowland, et al.
Journal of Medical Internet Research|June 21, 2021
Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort StudyRichard John Woodman, Kimberley Bryant, Michael J Sorich, et al.
Translational Lung Cancer Research|March 18, 2024
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature reviewYibing Bai, Wenyu Yang, Lukas Käsmann, et al.
British Journal of Cancer|May 27, 2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial dataMichael J Sorich, Andrew Rowland, Ganessan Kichenadasse, et al.
Breast Cancer Research and Treatment|August 11, 2019
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patientsEthan Tang, Andrew Rowland, Ross A McKinnon, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumabAshley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, et al.
Seminars in Oncology|November 19, 2019
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitorsAshley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
European Urology|July 15, 2020
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Journal of the National Cancer Institute|August 27, 2021
RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerAshley M Hopkins, Ganessan Kichenadasse, Jessica M Logan, et al.
Pageof 22

Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
BMC Cancer|February 28, 2020
Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trialsAshley M Hopkins, Akash D Rathod, Andrew Rowland, et al.
Journal of Medical Internet Research|June 21, 2021
Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort StudyRichard John Woodman, Kimberley Bryant, Michael J Sorich, et al.
Translational Lung Cancer Research|March 18, 2024
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature reviewYibing Bai, Wenyu Yang, Lukas Käsmann, et al.
British Journal of Cancer|May 27, 2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial dataMichael J Sorich, Andrew Rowland, Ganessan Kichenadasse, et al.
Breast Cancer Research and Treatment|August 11, 2019
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patientsEthan Tang, Andrew Rowland, Ross A McKinnon, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumabAshley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, et al.
Seminars in Oncology|November 19, 2019
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitorsAshley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
European Urology|July 15, 2020
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Journal of the National Cancer Institute|August 27, 2021
RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerAshley M Hopkins, Ganessan Kichenadasse, Jessica M Logan, et al.
Pageof 22